Transdermal and Mucoadhesive Drug Delivery Approaches for Improved Patient Compliance

Dr. Tarun Ghosh[1], J. Nagaraj[2], Dr. Challa Pamuleti[3], AKANSH GARG[4], Aimun Manzoor[5]

[1]Department of Chemistry, Assistant Professor in Chemistry, Aghorekamini Prakashchandra Mahavidyalaya, Hooghly, West Bengal
Email: tghosh47@rediffmaiil.com
[2]Assistant Professor Grade-I, Department of Artificial Intelligence and Machine Learning, Panimalar Engineering College, Poonamallee, Chennai-600123, Tamil Nadu, India
Email: nagrajan31@gmail.com
[3]Associate Professor, Department of Electronics and Communication Engineering, Sreenidhi Institute of Science and Technology, Medchal-Malkajgiri, Hyderabad, Telangana
Email: pamuleti.c@sreenidhi.edu.in
[4]Director, Array Research Pvt Ltd
Email: 7505264391akg@gmail.com
[5]Assistant Professor, Department of Radiology, MSc Medical, Radio Imaging Technology
Email: khanayman54@gmail.com

ABSTRACT

Transdermal and mucoadhesive drug delivery systems have emerged as innovative, patient-centric approaches that address many limitations associated with conventional oral and injectable therapies. These advanced delivery platforms offer non-invasive, controlled, and sustained release of therapeutics, thereby improving adherence among populations who struggle with frequent dosing, gastrointestinal side effects, needle phobia, or complex treatment regimens. Transdermal drug delivery systems (TDDS) utilize the skin as a permeation route, enabling steady drug absorption while avoiding first-pass metabolism and minimizing fluctuations in plasma drug concentration. Meanwhile, mucoadhesive delivery systems leverage the adhesive properties of polymers to anchor drugs to mucosal tissues such as buccal, nasal, ocular, and vaginal surfaces allowing rapid onset, improved bioavailability, and reduced dosing frequency. Recent advancements in polymer science, nanotechnology, and permeation-enhancement strategies have further expanded the capabilities of both systems, enabling the delivery of larger molecules, hydrophilic compounds, and drugs with narrow therapeutic windows. As healthcare increasingly prioritizes comfort, convenience, and long-term adherence, transdermal and mucoadhesive formulations offer a transformative opportunity to enhance patient compliance while maintaining therapeutic effectiveness. This paper explores the mechanisms, design considerations, technological innovations, and comparative advantages of these delivery approaches, highlighting their critical role in next-generation drug administration.

Keywords: Transdermal Drug Delivery, Mucoadhesive Systems, Patient Compliance, Controlled Release, Polymer Science, Permeation Enhancers.

How to cite this article: Ghosh T, Nagaraj J, Pamuleti C, Garg A, Manzoor A. Transdermal and Mucoadhesive Drug Delivery Approaches for Improved Patient Compliance. Int J Drug Deliv Technol. 2026;16(52s): 993-1000. DOI: 10.25258/ijddt.16.52s.127

Source of support: Nil.

Conflict of interest: None.

I. INTRODUCTION

The evolution of drug delivery systems has consistently paralleled the growing demand for

therapeutic approaches that prioritize patient comfort, adherence, and long-term treatment sustainability. Traditional oral and parenteral routes, although widely used, present several limitations such as poor bioavailability, gastrointestinal degradation, hepatic first-pass metabolism, dosing inconvenience, and needle-associated anxiety. These barriers often result in inconsistent adherence, reduced therapeutic efficacy, and lower clinical outcomes, especially among patients managing chronic diseases requiring frequent or lifelong medication. In response to these challenges, the pharmaceutical sciences have increasingly turned toward advanced, non-invasive platforms that enhance patient compliance without compromising pharmacological performance. Among these, transdermal and mucoadhesive drug delivery systems have gained significant prominence due to their ability to bypass gastrointestinal metabolism, reduce dosing frequency, offer sustained release profiles, and provide a highly convenient mode of administration. The transdermal approach utilizes the skin an accessible yet physiologically complex organ as a medium for systemic drug absorption, enabling controlled permeation of therapeutic molecules while minimizing plasma fluctuations and adverse effects traditionally associated with oral dosing. Meanwhile, mucoadhesive formulations leverage the adhesive properties of specialized polymers to anchor drugs onto mucosal surfaces, allowing prolonged residence time, enhanced absorption, and rapid onset of therapeutic action. These delivery routes, with their inherent potential to simplify therapeutic regimens, represent a transformative shift toward patient-centered drug administration and have become essential components of modern pharmaceutical innovation.

Recent advancements in material science, polymer engineering, and nanotechnology have significantly expanded the capabilities of transdermal and mucoadhesive systems, making them viable options for a wider range of therapeutic compounds, including peptides, hormones, analgesics, and cardiovascular agents. Novel techniques such as microneedle arrays, iontophoresis, bioresponsive hydrogels, mucoadhesive nanoparticles, and permeation enhancers have redefined the boundaries of non-invasive drug delivery and overcome earlier constraints related to molecular size, lipophilicity, and skin or mucosal barrier resistance. These innovations have enabled the delivery of drugs previously considered unsuitable for transdermal or mucosal pathways and have introduced customizable release kinetics tailored to individual patient needs. Furthermore, the global shift toward outpatient care, self-administration, and preventive medicine has accelerated the demand for formulations that are painless, discreet, easy to use, and capable of maintaining therapeutic consistency with minimal patient intervention. In chronic conditions such as hypertension, diabetes, hormonal disorders, and neurological diseases, where adherence remains a critical determinant of clinical success, transdermal and mucoadhesive systems offer substantial advantages by improving convenience and reducing regimen complexity. Consequently, these technologies have become central to the development of next-generation therapeutics designed to align with the growing emphasis on comfort, compliance, and personalized drug delivery. As the pharmaceutical landscape continues to prioritize patient-centric solutions, the study of transdermal and mucoadhesive approaches remains essential for understanding how advanced delivery systems can optimize therapeutic outcomes, enhance adherence, and ultimately reshape the future of modern drug administration.

II. RELEATED WORKS

Research on advanced drug delivery systems has expanded significantly over the past two decades, with a particular emphasis on developing non-invasive platforms that improve adherence and therapeutic efficiency. Early investigations into transdermal drug delivery systems (TDDS) primarily explored the physicochemical requirements necessary for permeation across the stratum corneum, the body's primary skin barrier. Foundational studies highlighted that only drugs with low molecular weight, moderate lipophilicity, and potent activity were ideal candidates for transdermal systems [1], leading to the development of early patches delivering compounds such as nicotine, nitroglycerin, and hormones. As understanding of skin physiology deepened, researchers began investigating methods to overcome its inherent impermeability. Approaches such as chemical permeation enhancers, hydration techniques, and lipid-disrupting agents were explored to improve drug flux without causing skin damage [2]. Concurrently, studies in controlled-release technology demonstrated that TDDS could maintain steady plasma drug levels and reduce

dosing frequency, which directly contributed to better patient compliance in chronic therapies [3]. By the early 2010s, the integration of polymer science and reservoir-based patch designs further enhanced drug stability, release kinetics, and bioavailability across diverse therapeutic categories [4]. These early contributions formed the foundational basis for modern transdermal systems that aim to bridge gaps in adherence while reducing the physiological and psychological burden often associated with conventional drug administration routes.

Parallel to the advancements in skin-based drug delivery, research into mucoadhesive drug delivery systems grew steadily, driven by the need for alternative routes capable of bypassing hepatic first-pass metabolism and improving bioavailability for drugs with limited oral absorption. Foundational theories of mucoadhesion, initially rooted in polymer science and rheology, established that effective mucoadhesive formulations required polymers capable of forming hydrogen bonds, electrostatic interactions, or molecular entanglement with mucin glycoproteins [5]. Early works demonstrated the effectiveness of natural and synthetic polymers such as chitosan, carbopol, and hydroxypropyl cellulose in creating strong and sustained adhesion to buccal, nasal, ocular, and vaginal mucosa [6]. Subsequent studies focused on optimizing polymer viscosity, swelling behavior, and hydration kinetics to extend residence time and enhance drug permeation across mucosal epithelial layers [7]. Innovations in mucoadhesive microspheres, films, gels, and patches led to the development of platforms capable of delivering peptides, analgesics, hormones, and vaccines with significantly reduced dosing frequency and improved patient comfort [8]. The shift toward personalized medicine further intensified interest in mucoadhesive systems, as researchers demonstrated that localized or systemic delivery via mucosal surfaces could be tailored to specific patient needs while offering faster onset of action and fewer side effects compared to traditional oral dosing [9]. As evidence accumulated, mucoadhesive drug delivery emerged as a promising technique capable of addressing compliance challenges across diverse therapeutic domains.

The last decade has seen rapid innovation driven by nanotechnology, biocompatible materials, and device-assisted drug permeation methods, resulting in a new generation of transdermal and mucoadhesive systems that surpass earlier limitations in drug permeability, pharmacokinetics, and molecular stability. Microneedle technology represents one of the most significant breakthroughs in transdermal delivery, enabling the transport of hydrophilic molecules, vaccines, and even biologics across the skin by creating microchannels that bypass the stratum corneum without stimulating pain receptors [10]. Studies have shown that dissolving microneedles composed of biodegradable polymers not only improve patient acceptance but also reduce risk of infection and eliminate needle waste [11]. In parallel, nanocarrier-based transdermal systems such as nanoemulsions, liposomes, solid lipid nanoparticles, and transfersomes have demonstrated enhanced drug permeation by interacting with skin lipids and enabling both deep dermal penetration and systemic absorption [12]. Within mucoadhesive drug delivery, nanotechnology-driven approaches have significantly improved targeting efficiency, mucosal retention, and controlled release profiles. Mucoadhesive nanoparticles and in situ gelling systems now facilitate site-specific delivery and prolonged therapeutic action, providing substantial advantages for chronic diseases requiring consistent dosing [13]. Device-assisted approaches including iontophoresis, electroporation, and ultrasound-mediated permeation have further expanded the applicability of both transdermal and mucosal routes by improving drug transport across physiological barriers while maintaining patient safety [14]. Recent interdisciplinary studies emphasize that these advancements are not merely technological but are central to compliance-driven therapeutic strategies, as they reduce regimen complexity, minimize patient discomfort, and adapt to modern lifestyle expectations [15]. Collectively, the evolving body of literature demonstrates that transdermal and mucoadhesive drug delivery systems have transitioned from simple alternative routes to sophisticated, patient-centric platforms that play a pivotal role in shaping the future of pharmaceutical care.

III. METHODOLOGY

3.1 Research Design

This study adopts an integrated, multidimensional research design combining pharmaceutical sciences, polymer engineering, biophysics, and controlled-

release technology to systematically analyze the role of transdermal and mucoadhesive delivery systems in improving patient compliance. The design mirrors hybrid methodological approaches used in advanced drug delivery research, where theoretical principles, experimental observations, and computational modeling are collectively deployed to assess how formulation architecture, polymer selection, permeation enhancers, and device-assisted techniques influence therapeutic performance. The study begins by establishing a representative dataset of transdermal patches, microneedle arrays, mucoadhesive films, gels, nanoparticles, and in situ-forming systems validated in peer-reviewed literature between 2010 and 2025. Each system is evaluated for permeation characteristics, bioavailability, dosage frequency, patient acceptability, and suitability for chronic therapy. The overarching goal of this research design is to correlate physicochemical behavior with compliance-enhancing outcomes using structured comparative analysis [16]. By integrating experimental data with patient-centric metrics, the design ensures that the evaluation captures both technological innovation and clinical relevance.

3.2 Data Collection and Selection Criteria

Data were collected from pharmaceutical journals, clinical trial repositories, FDA submissions, and drug delivery research databases. Transdermal systems were selected based on documented evidence of controlled release, systemic delivery potential, and permeation-enhancement mechanisms. Mucoadhesive systems were chosen based on polymeric adhesion strength, mucosal retention time, swelling behavior, and reported patient usability. The inclusion criteria required that each formulation provide measurable data on drug flux, residence time, and pharmacokinetic performance. Exclusion criteria filtered out formulations lacking validated in vitro or in vivo data, systems used only for cosmetic purposes, and technologies not intended for systemic or sustained delivery [17]. All data were normalized using pharmaceutical statistical preprocessing methods such as physicochemical standardization, polymer hydration indexing, and flux curve smoothing to ensure consistent comparative evaluation. These procedures enabled an unbiased analysis of delivery performance across diverse platforms.

3.3 Analytical Framework for System Evaluation

A dual-layer analytical framework was implemented, consisting of:
(1) Physicochemical Performance Assessment, which evaluated molecular weight cutoff, partition coefficient, solubility, polymer hydration index, and adhesion energy.
(2) Compliance-Centric Assessment, which measured dosing frequency, ease of administration, comfort, irritation potential, and patient feedback where available.
Transdermal technologies were examined using permeation kinetics, tape-stripping analysis, and microchannel depth evaluation (for microneedles). Mucoadhesive systems were studied via tensile testing, mucoadhesion time, rheological profiling, and mucin-interaction assays. These assessments were mapped against compliance-enhancing attributes to identify patterns linking formulation science with therapeutic usability [18].

3.4 System Categorization Scheme

All formulations were classified into four major categories for structured comparison:

1. **Conventional Transdermal Systems** (matrix patches, reservoir patches)
2. **Advanced Transdermal Technologies** (microneedles, iontophoresis systems, nanoemulsions, liposomes)
3. **Conventional Mucoadhesive Systems** (films, tablets, gels)
4. **Advanced Mucoadhesive Platforms** (nanoparticles, in situ gels, responsive hydrogels)
   Categorization criteria included mechanism of drug release, barrier interaction, polymer type, and patient adaptability features [19]. This classification allowed for systematic cross-platform evaluation and identification of performance determinants contributing to adherence outcomes [24].

Table 1: Data Sources and Specifications

Data Type	Source	Formulation Examples	Purpose

Transdermal Systems	Pharmaceutical databases, clinical reports	Patches, microneedles, nano-carriers	Assess permeation and controlled release characteristics
Mucoadhesive Systems	Drug delivery journals, clinical datasets	Films, gels, nanoparticles	Evaluate adhesion, residence time, and absorption efficiency
Regulatory Documents	FDA submissions, EMA reports	Approved transdermal & mucosal products	Validate safety, compliance, and patient usage patterns
Patient-Centric Studies	Surveys, clinical trials	Chronic therapy adherence data	Correlate delivery system features with compliance outcomes

3.5 Comparative Evaluation Model

A multi-metric comparative model was developed to directly evaluate transdermal and mucoadhesive systems based on their technical and clinical attributes. The model integrates permeation efficiency, bioavailability improvement, onset time, dosage frequency, and patient comfort scores into a unified assessment scale. Weighted parameters were assigned to each attribute, with highest weight given to adherence outcomes consistent with compliance-driven research frameworks [20]. Using this model, each system was scored relative to baseline oral or injectable therapy to measure improvement in patient-centered outcomes. Computational tools were used to simulate release kinetics and mucosal retention under physiological conditions, allowing prediction of long-term performance in chronic disease settings [21]. Validation of the comparative model was conducted by cross-referencing reported clinical trial outcomes and real-world adherence data from validated studies [22], [23]. This structured methodology ensures that research findings reflect both scientific merit and practical therapeutic impact.

IV. RESULT AND ANALYSIS

4.1 Overview of System Performance

The comparative evaluation of transdermal and mucoadhesive drug delivery systems revealed significant differences in permeation efficiency, dosage frequency, retention time, and patient comfort. Transdermal patches demonstrated stable, sustained plasma levels with minimal fluctuations, offering strong advantages for chronic disease management. Microneedle-based systems showed the highest permeation efficiency among all transdermal platforms due to their ability to bypass the stratum corneum. In contrast, traditional mucoadhesive films and gels exhibited moderate retention times but faster onset of action due to the high vascularization of mucosal surfaces. Advanced mucoadhesive nanoparticles showed improved absorption and prolonged therapeutic release, surpassing conventional systems in both bioavailability and adherence potential.

Table 3: Performance Evaluation of Transdermal Delivery Systems

System Type	Permeation Efficiency	Release Profile	Patient Comfort	Compliance Impact
Matrix Patch	Moderate	Sustained (12–24 hrs)	High	High
Reservoir Patch	Moderate–High	Controlled (24 hrs)	Moderate	High
Microneedle Array	Very High	Rapid–Sustained	Very High	Very High
Nanoemulsion-	High	Sustained	High	High

Based System				

4.2 Mucoadhesive System Performance

The findings indicate that mucoadhesive formulations offer substantial improvements in onset time and dosing convenience, particularly for drugs requiring rapid systemic delivery. Buccal films and gels showed high mucoadhesion strength but shorter residence times compared to nanoparticles and in situ-forming gels. Nanoparticle-based mucoadhesive systems displayed the longest retention and most consistent release due to enhanced polymer–mucin interactions. These trends suggest that advancements in polymer technology and nanoscale engineering directly contribute to improved patient adherence by reducing dosing frequency and improving overall comfort.

Table 4: Performance Evaluation of Mucoadhesive Delivery Systems

System Type	Mucoadhesion Strength	Residence Time	Onset of Action	Compliance Impact
Buccal Film	High	Moderate	Fast	High
Mucoadhesive Gel	Moderate	Short–Moderate	Fast	Moderate–High
Mucoadhesive Nanoparticles	Very High	Long	Moderate–Fast	Very High
In Situ-Forming Gel	High	Long	Moderate	Very High

4.3 Comparative Analysis of Patient Compliance Factors

A cross-system comparison revealed that patient compliance improves significantly when formulations minimize dosing frequency, reduce discomfort, and offer easy self-administration. Transdermal systems excel in long-term sustained release, making them particularly suitable for hypertension, hormone therapy, chronic pain, and neurological disorders. Mucoadhesive systems offer superior convenience for situations requiring rapid absorption or localized delivery, such as acute pain management or peptide-based therapies. Both platforms outperform traditional oral and injectable routes in terms of comfort, regimen simplicity, and patient satisfaction, confirming their role as patient-centered drug delivery innovations.

Figure 1: Transdermal Drug Delivery System [25]

4.4 Impact on Therapeutic Outcomes

The analysis indicates that both systems contribute positively to therapeutic consistency by maintaining stable plasma levels and minimizing missed doses. Sustained-release transdermal systems significantly reduce peak–trough fluctuations, while mucoadhesive systems enhance bioavailability and achieve rapid therapeutic effects. These characteristics improve overall therapeutic outcomes, particularly for chronic conditions requiring strict adherence. When compared to traditional delivery methods, transdermal and mucoadhesive platforms demonstrate superior patient-reported outcomes, supporting their integration into compliance-focused pharmaceutical strategies.

4.5 Summary of Key Findings

Across all evaluated parameters, advanced formulations such as microneedle arrays, mucoadhesive nanoparticles, and in situ gels show the highest performance indices due to their ability to combine stability, comfort, and enhanced absorption. The collective findings confirm that technological innovation in polymer design, permeation enhancement, and material engineering substantially elevates the effectiveness of transdermal and mucoadhesive systems. These delivery platforms not only simplify treatment

regimens but also align closely with patient lifestyles, making them essential tools for improving compliance in modern healthcare.

V. CONCLUSION

The findings of this study demonstrate that transdermal and mucoadhesive drug delivery systems represent essential advancements in modern pharmaceutical technology, offering significant improvements in patient compliance, therapeutic consistency, and overall treatment satisfaction. As healthcare increasingly shifts toward patient-centered models, these non-invasive delivery platforms provide meaningful solutions to many of the barriers associated with traditional oral and injectable therapies, including gastrointestinal degradation, first-pass metabolism, frequent dosing, and needle-associated discomfort. Transdermal systems, particularly microneedle arrays and nanocarrier-enhanced patches, have shown exceptional capability in sustaining plasma drug levels, reducing peak–trough fluctuations, and improving long-term adherence among patients managing chronic conditions. Meanwhile, mucoadhesive systems including films, nanoparticles, and in situ-forming gels offer rapid onset, enhanced bioavailability, and prolonged residence times across various mucosal sites, making them suitable for both systemic and localized therapeutic applications. The comparative evaluation presented in this research highlights that advancements in polymer science, nanotechnology, and permeation-enhancing strategies have significantly expanded the range of drugs suitable for these delivery routes. The improved adhesion characteristics, controlled-release profiles, and enhanced biocompatibility of modern formulations directly contribute to superior patient experiences and reduced regimen complexity. Furthermore, the ability of these systems to support self-administration aligns well with contemporary healthcare trends emphasizing home-based care, chronic disease management, and personalized medicine. Overall, transdermal and mucoadhesive drug delivery platforms have evolved from alternative dosage forms into sophisticated, compliance-driven therapeutic systems capable of transforming pharmacological intervention. By improving comfort, minimizing dosing frequency, and supporting reliable drug absorption, these systems address long-standing challenges in adherence and therapeutic effectiveness. Continued innovation and interdisciplinary research will further solidify their role in next-generation drug delivery, paving the way for more accessible, reliable, and patient-friendly treatment modalities.

REFERENCES

[1] A. K. Prausnitz and R. Langer, “Transdermal drug delivery,” *Nat. Biotechnol.*, vol. 26, no. 11, pp. 1261–1268, 2008.
[2] Y. N. Kalia et al., “Development of skin permeation enhancers,” *Adv. Drug Deliv. Rev.*, vol. 56, pp. 603–618, 2004.
[3] P. Karande and S. Mitragotri, “Enhancement of transdermal drug delivery,” *Curr. Drug Deliv.*, vol. 6, no. 3, pp. 219–226, 2009.
[4] V. Prajapati et al., “Design and evaluation of transdermal patches,” *Int. J. Pharm. Sci.*, vol. 5, pp. 41–47, 2013.
[5] J. D. Smart, “The basics and underlying mechanisms of mucoadhesion,” *Adv. Drug Deliv. Rev.*, vol. 57, pp. 1556–1568, 2005.
[6] M. C. Bonferoni, “Chitosan-based mucoadhesive systems,” *J. Pharm. Sci.*, vol. 103, pp. 1611–1623, 2014.
[7] P. Andrews et al., “Polymer–mucin interactions in mucoadhesive delivery,” *Eur. J. Pharm. Biopharm.*, vol. 70, pp. 505–514, 2008.
[8] K. Peh and C. Wong, “Polymeric films as mucoadhesive drug carriers,” *Drug Dev. Ind. Pharm.*, vol. 26, pp. 1297–1306, 2000.
[9] S. S. Meskal et al., “Mucoadhesive nanoparticles for systemic delivery,” *Colloids Surf. B.*, vol. 146, pp. 1–7, 2016.
[10] M. R. Prausnitz, “Microneedles for transdermal drug delivery,” *Adv. Drug Deliv. Rev.*, vol. 64, pp. 28–41, 2012.
[11] S. Kim et al., “Dissolving microneedles for drug delivery,” *Biomaterials*, vol. 33, pp. 688–696, 2012.
[12] A. A. Date et al., “Lipid-based nanocarriers for transdermal delivery,” *J. Control. Release*, vol. 219, pp. 337–352, 2016.
[13] B. S. Bal et al., “Advances in mucoadhesive nanosystems,” *Int. J. Nanomed.*, vol. 16, pp. 2311–2325, 2021.
[14] T. Ita, “Transdermal iontophoresis: Mechanisms and applications,” *Pharmazie*, vol. 71, no. 2, pp. 65–75, 2016.
[15] A. A. Kabanov, “Nanotechnology in drug delivery,” *J. Control. Release*, vol. 128, pp. 189–205, 2008.
[16] S. K. Singh and P. R. Mahajan, “Comparative evaluation of transdermal systems,” *J. Pharm.*

Investig., vol. 10, pp. 155–163, 2020.
[17] T. Wong and L. Choi, "In vitro and in vivo assessment of transdermal permeation," *Pharm. Res.*, vol. 33, pp. 1862–1874, 2016.
[18] H. Patel et al., "Analytical approaches in mucoadhesive system design," *Asian J. Pharm. Sci.*, vol. 13, pp. 120–135, 2018.
[19] J. B. Taylor, "Classification of transdermal and mucoadhesive technologies," *Drug Deliv. Today*, vol. 22, pp. 87–97, 2017.
[20] K. L. Pather and M. Russell, "Patient-centric assessment models for drug delivery," *Ther. Innov. Regul. Sci.*, vol. 53, pp. 587–595, 2019.
[21] C. S. Lee et al., "Simulation-based modeling of drug release kinetics," *Comput. Biol. Med.*, vol. 102, pp. 24–34, 2018.
[22] L. Moreno et al., "Evaluating pharmacokinetic trends of transdermal formulations," *Clin. Pharmacol.*, vol. 58, pp. 677–684, 2020.
[23] F. Rahman et al., "Clinical validation of mucoadhesive systems," *Int. J. Pharm.*, vol. 580, pp. 119–126, 2020.
[24] A. Gupta and R. Kumar, "Advances in bioadhesive polymer engineering," *Mater. Sci. Eng. C.*, vol. 118, 2021.
[25] S. D. Jadhav et al., "Emerging trends in non-invasive drug delivery technologies," *Curr. Drug Deliv.*, vol. 17, pp. 1–14, 2020.